Plain-English translation of NCT07821658 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Alzheimer's Disease research guide →This is a 10-year safety monitoring study of lecanemab-irmb, a recently approved medication for Alzheimer's disease. Rather than a traditional research clinic visit, the study collects information from an existing national registry (ALZ-NET) that follows patients who are being treated with new Alzheimer's therapies. Researchers will use this real-world data to monitor how safe and effective the medication is as it's used by patients and doctors in everyday medical practice.
Even though the FDA has approved this medication, doctors and patients need ongoing information about how it performs and what side effects might occur when used by many different people over many years. This long-term safety tracking helps ensure the treatment remains safe and benefits patients in real-world conditions, not just in controlled research settings.
You likely qualify if…
You likely don't qualify if…
If you join this study, your doctor will continue treating you with the medication as usual according to FDA guidelines—your care doesn't change. The research team will collect information from your medical records and the ALZ-NET registry over the next 10 years to track how you're doing and whether you experience any side effects. You won't need to do anything extra beyond your regular Alzheimer's care appointments.
AI-generated summary from trial data · Nov 17, 2026 · Not medical advice
United States
Enrollment target
~6,700 participants
Started
May 2025
Primary completion
January 2035
Last updated on clinicaltrials.gov in September 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Eisai Medical Information
Eisai Inc.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.